The Joint Cancer Research Unit CIPF-IVO (JCRU CIPF-IVO) was created with the objective of enhancing the translational research of both institutions through the incorporation of experts in different areas of knowledge, as well as resources that enhance the synergism of the research areas of each of the centers.

The JCRU CIPF-IVO is integrated by researchers from the Laboratory of Therapeutic Polymers and the Department of Computational Genomics of the CIPF, as well as the Laboratory of Molecular Biology and Biobank of the IVO that develop similar and complementary research lines in the field of oncology research with applications In Biomedicine.

The main lines of research are currently focused on the identification and validation of new biomarkers in different tumors such as prostate, breast and gynecological cancers to define different molecular biotypes on which to develop more effective therapeutic strategies.

This JCRU represents an efficient model of what a translational research means: to incorporate the knowledge obtained from in vitro and in vivo models into the appropriate clinical context. This results in the definition of new biomarkers or diagnostic tools as well as in the definition of new therapeutic combinations as well as developments of new drugs (nanomedicine) that lead to clinical trials that demonstrate their effectiveness into the appropriate context of the disease.


Get to know us better

Research Staff

The people who make it all possible

José Antonio López Guerrero

María García Flores

Antonio Fernández Serra

Raquel López Reig


Our scientific contributions

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
Scientific Reports, 2021 Feb,  DOI:  10.1038/s41598-021-82671-w,  Vol. 11,  pag. 4433-4433

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.
Fernandez-Serra A, Moura DS, Sanchez-Izquierdo MD, Calabuig-Fariñas S, Lopez-Alvarez M, Martínez-Martínez A, Carrasco-Garcia I, Ramírez-Calvo M, Blanco-Alcaina E, López-Reig R, Obrador-Hevia A, Alemany R, Gutierrez A, Hindi N, Poveda A, Lopez-Guerrero JA and Martin-Broto J
Cancers, 2020 Oct,  DOI:  10.3390/cancers12102979,  Vol. 12,  pag. 

Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
Leskela S, Romero I, Rosa-Rosa JM, Caniego-Casas T, Cristobal E, Pérez-Mies B, Gutierrez-Pecharroman A, Santón A, Ojeda B, López-Reig R, Palacios-Berraquero ML, Andrada E, Montes S, Pastor F, Gomez MC, López-Guerrero JA, Poveda A and Palacios J
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020 Jul,  DOI:  10.1097/PAS.0000000000001478,  Vol. 44,  pag. 982-990

A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types.
Pastor-Navarro B, García-Flores M, Fernández-Serra A, Blanch-Tormo S, Martínez de Juan F, Martínez-Lapiedra C, Maia de Alcantara F, Peñalver JC, Cervera-Deval J, Rubio-Briones J, García-Rupérez J and López-Guerrero JA
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020 Apr,  DOI:  10.3390/ijms21082783,  Vol. 21,  pag. 

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.
Martin-Broto J, Cruz J, Penel N, Le Cesne A, Hindi N, Luna P, Moura DS, Bernabeu D, de Alava E, Lopez-Guerrero JA, Dopazo J, Peña-Chilet M, Gutierrez A, Collini P, Karanian M, Redondo A, Lopez-Pousa A, Grignani G, Diaz-Martin J, Marcilla D, Fernandez-Serra A, Gonzalez-Aguilera C, Casali PG, Blay JY and Stacchiotti S
LANCET ONCOLOGY, 2020 Mar,  DOI:  10.1016/S1470-2045(19)30826-5,  Vol. 21,  pag. 456-466



Thank you for supporting us